The potential predictive value of serum srCaS1 levels for overall survival in endometrial cancer

Abstract

Objectives:The main aim of the study was to evaluate the impact of levels of serum soluble receptor-binding cancer antigen expressed on SiSo cells (sRCAS1) on the overall survival (OS) rates in patients with endometrial cancer. Furthermore, we analyzed sRCAS1 levels according to the clinicopathological characteristics of the disease. Material and methods:The study group comprised 43 patients who were being treated for endometrial cancer. We included 10 low-risk, 20 intermediate-risk and 13 high-risk endometrial cancers using the criteria of the European Society for Medical Oncology (ESMO), the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Gynaecological Oncology (ESGO). Serum sRCAS1 levels were obtained before and after surgery. Serum sRCAS1 levels were assessed using the ELISA method. Results:In our univariate analysis, both the pre-and post-surgery high sRCAS1 groups of patients with endometrial cancer indicated a shortened OS. However, in our multivariate analysis, when patients' age and disease-related risk was taken into consideration, only the post-surgery sRCAS1 levels remained as independent prognostic factors of a poor OS. Pre-treatment serum sRCAS1 levels were statistically significantly higher than post-surgery sRCAS1 levels; however, the difference between pre-and post-surgery sRCAS1 levels did not influence the patients' OS rate. Pre-and post-surgery sRCAS1 levels did not differ according to tumor grade, stage of the disease or the disease-related risk group. Conclusions:High post-surgery serum sRCAS1 levels seem to be an independent indicator of shortened overall survival in patients with endometrial cancer.

High post‐treatment serum soluble receptor‐binding cancer antigen expressed on SiSo cells (sRCAS1) levels is associated with poor survival of patients with cervical cancer

“…In contrast, the pre‐treatment sRCAS1 and the alteration in sRCAS1 levels before and after the treatment were not related to the long‐term outcome for the patient. We had achieved similar results in our previous study that was focused on serum sRCAS1 levels in patients with endometrial cancer, where we found that post‐surgery serum sRCAS1 alone was associated with patient survival . Because of the strong immunosuppressive effect of the RCAS1, our results suggest that the intensity of the selective suppression of the host's immune system at the end of the primary treatment exerts the observed impact on the patient prognosis.…”

“…We had achieved similar results in our previous study that was focused on serum sRCAS1 levels in patients with endometrial cancer, where we found that post-surgery serum sRCAS1 alone was associated with patient survival. 28 Because of the strong immunosuppressive effect of the RCAS1, our results suggest that the intensity of the selective suppression of the host's immune system at the end of the primary treatment exerts the observed impact on the patient prognosis. On the other hand, pretreatment serum sRCAS1 levels may correlate with cancer incidence, and serum sRCAS1 levels were found to be higher in several of the study group neoplasms compared with levels on the healthy controls.…”

Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy (Review)

“…Additionally, RCAS1 expression and metastasis were clinically significant predictors of OS according to multivariate analysis (72). Recently, Szubert et al (73) suggested that high levels of RCAS1 in post-surgery serum are an independent p redictor of shortened OS time in patients with EC.…”